search
Back to results

Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients (COVID_OFF)

Primary Purpose

Infertility, COVID, IVF

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Blood sample
Sponsored by
CRG UZ Brussel
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Infertility

Eligibility Criteria

undefined - 45 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female
  • Undergoing IVF/ICSI treatment
  • Planned for an oocyte retrieval
  • PCR positive of SARS-CoV-2 or high suspicion for COVID 19 based on CT scan
  • Signed informed consent

Exclusion Criteria:

  • None

Sites / Locations

  • Uz Brussels

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Diagnostic arm

Arm Description

Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells

Outcomes

Primary Outcome Measures

Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium
Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval

Secondary Outcome Measures

Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium
Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2

Full Information

First Posted
May 27, 2020
Last Updated
February 16, 2022
Sponsor
CRG UZ Brussel
search

1. Study Identification

Unique Protocol Identification Number
NCT04425317
Brief Title
Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients
Acronym
COVID_OFF
Official Title
Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
September 10, 2020 (Actual)
Primary Completion Date
June 1, 2021 (Actual)
Study Completion Date
January 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
CRG UZ Brussel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Recently, the world was shaken awake by a pandemic caused by a novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). In most nations drastic isolation measures were taken to minimize the further spread of the Coronavirus Disease 2019 (COVID-19). Being the first pandemic sparked by a Coronavirus, little was known on COVID-19 and its implications on general health. Our understanding on the virus and its potential effects on health is growing. In Belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. As also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. The limited evidence of SARS-CoV-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active SARS-CoV-2 infection on female gametes. Viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out. Since the onset of the pandemic, knowledge about the molecular details of SARS-CoV-2 infection rapidly grew. Coronaviruses are enveloped RNA viruses. For a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. The coronavirus surface protein spike (S) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. The SARS-CoV-2-S protein (SARS-S) utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry. Host proteases such as transmembrane serine protease 2 (TMPRSS2) are then needed to cleave the viral S protein, allow-ing permanent fusion of the viral and host cell membranes2. Expression of ACE2 and TMPRSS2 has been shown in testicular, uterine and placental cells. Based on available transcriptomic data, co-expression of ACE2 and TMPRSS2 is also seen on oocyte level, but the possible impact on reproduction is unknown. The BSG (basigin or CD147), a receptor on host cells, was also identified as a possible route for viral invasion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, COVID, IVF

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Diagnostic arm
Arm Type
Other
Arm Description
Blood sample and endometrial biopsy Collection of follicular fluid, immature oocytes and cumulus cells
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood sample
Other Intervention Name(s)
Endometrial biopsy
Intervention Description
Blood sample and endometrial biopsy on the moment of oocyte retrieval
Primary Outcome Measure Information:
Title
Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium
Description
Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium
Description
Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2
Time Frame
1 day

10. Eligibility

Sex
Female
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female Undergoing IVF/ICSI treatment Planned for an oocyte retrieval PCR positive of SARS-CoV-2 or high suspicion for COVID 19 based on CT scan Signed informed consent Exclusion Criteria: None
Facility Information:
Facility Name
Uz Brussels
City
Brussels
ZIP/Postal Code
1090
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
35272846
Citation
Boudry L, Essahib W, Mateizel I, Van de Velde H, De Geyter D, Pierard D, Waelput W, Uvin V, Tournaye H, De Vos M, De Brucker M. Undetectable viral RNA in follicular fluid, cumulus cells, and endometrial tissue samples in SARS-CoV-2-positive women. Fertil Steril. 2022 Apr;117(4):771-780. doi: 10.1016/j.fertnstert.2021.12.032. Epub 2022 Jan 1.
Results Reference
derived

Learn more about this trial

Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients

We'll reach out to this number within 24 hrs